TipRanks on MSN10h
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first ...
Business Insider16h
Promising Potential of Aclaris Therapeutics’ BSI-045B and Pipeline Elevates Buy Rating
Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...
Newsable Asianet News on MSN2h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps
Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...